NRX Pharmaceuticals (NRXP) Shares Outstanding (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Shares Outstanding (Entity) of $33.5 million for Q1 2026, up 95.51% year-over-year from $17.1 million in Q1 2025, and up 56.4% quarter-over-quarter from $21.4 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Shares Outstanding (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Shares Outstanding (Entity) for 10 consecutive years, with $33.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 95.51% year-over-year to $33.5 million; the TTM figure through Mar 2026 stood at $33.5 million (up 95.51% YoY), while the FY2025 annual figure was $21.4 million, up 101.06% from the prior year.
- Shares Outstanding (Entity) grew to $33.5 million in Q1 2026 per NRXP's latest filing, from $21.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $33.5 million in Q1 2026 and bottomed at $6.6 million in Q4 2022.
- Historically, Shares Outstanding (Entity) has averaged $12.6 million across 5 years, with a median of $9.8 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 2378.99% — and 2023, when it advanced 5.5%.
- NRX Pharmaceuticals' Shares Outstanding (Entity) stood at $6.6 million in 2022, then increased by 26.3% to $8.4 million in 2023, then increased by 26.84% to $10.6 million in 2024, then soared by 101.06% to $21.4 million in 2025, then surged by 56.4% to $33.5 million in 2026.
- Business Quant data shows NRXP's Shares Outstanding (Entity) at $33.5 million in Q1 2026, $21.4 million in Q4 2025, and $22.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 37.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.33 Mn |
| Dec 31, 2025 | 21.40 Mn |
| Sep 30, 2025 | 22.23 Mn |
| Jun 30, 2025 | 17.93 Mn |
| Mar 31, 2025 | 16.41 Mn |
| Dec 31, 2024 | 10.64 Mn |
| Sep 30, 2024 | 10.97 Mn |
| Jun 30, 2024 | 10.52 Mn |
| Mar 31, 2024 | 8.85 Mn |
| Dec 31, 2023 | 7.58 Mn |
| Sep 30, 2023 | 8.19 Mn |
| Jun 30, 2023 | 7.32 Mn |
| Mar 31, 2023 | 6.75 Mn |
| Dec 31, 2022 | 6.58 Mn |
| Sep 30, 2022 | 6.64 Mn |
| Jun 30, 2022 | 6.57 Mn |
| Mar 31, 2022 | 6.37 Mn |
| Dec 31, 2021 | 4.69 Mn |
| Sep 30, 2021 | 5.17 Mn |
| Jun 30, 2021 | 4.17 Mn |